Chiuhui Mary Wang

Chiuhui Mary Wang

Auto-generated profile, based on publicly available information

Chiuhui Mary Wang

Fondazione Telethon, Milan, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2011 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
TKTihana Kasic
Tihana Kasic
PCPiergiuseppe Colombo
Piergiuseppe Colombo
CScristiana soldani
cristiana soldani
CWChiuhui M. Wang
Chiuhui M. Wang
EMElena Miranda
Elena Miranda
AVAntonella Viola
Antonella Viola
Previous studies have suggested that T‐lymphocyte dysfunction might be attributable to nitrative stress induced by reactive nitrogen species (RNS). In this manuscript, we explored this hypothesis and provided a direct demonstration of the inhibitory effects of RNS on human T‐cell signaling, activation, and migration. We found that short exposure of human T cells to RNS induced tyrosine phosphorylation of several proteins, including the CD3ζ chain of the TCR complex, and release of Ca2+from intracellular stores. When the exposure to RNS was prolonged, T cells became refractory to stimulation, downregulated membrane receptors such as CD4, CD8, and chemokine receptors, and lost their ability to migrate in response to chemokines. Since substantial protein nitration, a hallmark of nitrative stress, was observed in various human cancers, intratumoral generation of RNS might represent a relevant mechanism for tumor evasion from immune surveillance.

11 September 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CWChiuhui Mary Wang
Chiuhui Mary Wang
AWAmy Heagle Whiting
Amy Heagle Whiting
ARAna Rath
Ana Rath
RARoberta Anido
Roberta Anido
DADiego Ardigò
Diego Ardigò
FMFlaminia Macchia
Flaminia Macchia
Improving health and social equity for persons living with a rare disease (PLWRD) is increasingly recognized as a global policy priority. However, there is currently no international alignment on how to define and describe rare diseases. A global reference is needed to establish a mutual understanding to inform a wide range of stakeholders for actions. A multi-stakeholder, global panel of rare disease experts, came together and developed an Operational Description of Rare Diseases. This reference describes which diseases are considered rare, how many persons are affected and why the rare disease population demands specific attention. The operational description of rare diseases is framed in two parts: a core definition of rare diseases, complemented by a descriptive framework of rare diseases. The core definition includes parameters that permit the identification of which diseases are considered rare, and how many persons are affected. The descriptive framework elaborates on the impact and burden of rare diseases on patients, their caregivers and families, healthcare systems, and society overall. The Operational Description of Rare Diseases establishes a common point of reference for decision-makers across the world who strive to understand and address the unmet needs of persons living with a rare disease. Adoption of this reference is essential to improving the visibility of rare conditions in health systems across the world. Greater recognition of the burden of rare diseases will motivate new actions and policies to address the unmet needs of the rare disease community.

2 February 2018 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
Sabina GainottiSabina Gainotti
Sabina Gainotti
PTPaola Torreri
Paola Torreri
CWChiuhui Mary Wang
Chiuhui Mary Wang
RRRobert Reihs
Robert Reihs
HMHeimo Müller
Heimo Müller
DTDomenica Taruscio
Domenica Taruscio
In rare disease (RD) research, there is a huge need to systematically collect biomaterials, phenotypic, and genomic data in a standardized way and to make them findable, accessible, interoperable and reusable (FAIR). RD-Connect is a 6 years global infrastructure project initiated in November 2012 that links genomic data with patient registries, biobanks, and clinical bioinformatics tools to create a central research resource for RDs. Here, we present RD-Connect Registry & Biobank Finder, a tool that helps RD researchers to find RD biobanks and registries and provide information on the availability and accessibility of content in each database. The finder concentrates information that is currently sparse on different repositories (inventories, websites, scientific journals, technical reports, etc.), including aggregated data and metadata from participating databases. Aggregated data provided by the finder, if appropriately checked, can be used by researchers who are trying to estimate the prevalence of a RD, to organize a clinical trial on a RD, or to estimate the volume of patients seen by different clinical centers. The finder is also a portal to other RD-Connect tools, providing a link to the RD-Connect Sample Catalogue, a large inventory of RD biological samples available in participating biobanks for RD research. There are several kinds of users and potential uses for the RD-Connect Registry & Biobank Finder, including researchers collaborating with academia and the industry, dealing with the questions of basic, translational, and/or clinical research. As of November 2017, the finder is populated with aggregated data for 222 registries and 21 biobanks.

1 January 2014 in Pathobiology
Verified
Journal Article
Open access
PDF file
LMLucia Monaco
Lucia Monaco
MCMarco Crimi
Marco Crimi
CWChiuhui Mary Wang
Chiuhui Mary Wang
Access to biological materials is a key prerequisite for scientific research in any medical field and in particular for research into rare diseases (RDs), for which obtaining high-quality samples and the related clinical data remains a major hurdle. RD biobanks play a pivotal role in making such materials and data available to the scientific community. In order to increase the effectiveness of RD biobanks, three major challenges need to be met: maximise access to rare biological samples stored in RD biobanks spread globally by the international scientific community, promote networking among such biobanks to share quality standards and procedures and allow collaboration with RD registries and databases, and finally adopt an efficient management model compliant with legal and ethical issues and ensuring biobank sustainability. The European program RD-Connect, funded under the FP7 program, addresses all of these issues through an articulated action plan aimed at building a network of European RD biobanks. Ultimately, RD-Connect will offer access to precious, quality-controlled biological samples from RD patients through an online, searchable, dynamic catalogue in the context of an integrated platform that links RD patient registries to biobanks and to clinical bioinformatics data for RD research.

24 October 2016 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CBChiara Baldo
Chiara Baldo
LCLorena Casareto
Lorena Casareto
ARAlessandra Renieri
Alessandra Renieri
Giuseppe MerlaGiuseppe Merla
Giuseppe Merla
BGBarbara Garavaglia
Barbara Garavaglia
MFMirella Filocamo
Mirella Filocamo
Rare diseases (RDs) are often neglected because they affect a small percentage of the population (6–8 %), which makes research and development of new therapies challenging processes. Easy access to high-quality samples and associated clinical data is therefore a key prerequisite for biomedical research. In this context, Genetic Biobanks are critical to developing basic, translational and clinical research on RDs. The Telethon Network of Genetic Biobanks (TNGB) is aware of the importance of biobanking as a service for patients and has started a dialogue with RD-Patient Organisations via promotion of dedicated meetings and round-tables, as well as by including their representatives on the TNGB Advisory Board. This has enabled the active involvement of POs in drafting biobank policies and procedures, including those concerning ethical issues. Here, we report on our experience with RD-Patient Organisations who have requested the services of existing biobanks belonging to TNGB and describe how these relationships were established, formalised and maintained. The process of patient engagement has proven to be successful both for lay members, who increased their understanding of the complex processes of biobanking, and for professionals, who gained awareness of the needs and expectations of the people involved. This collaboration has resulted in a real interest on the part of Patient Organisations in the biobanking service, which has led to 13 written agreements designed to formalise this process. These agreements enabled the centralisation of rare genetic disease biospecimens and their related data, thus making them available to the scientific community. The TNGB experience has proven to be an example of good practice with regard to patient engagement in biobanking and may serve as a model of collaboration between disease-oriented Biobanks and Patient Organisations. Such collaboration serves to enhance awareness and trust and to encourage the scientific community to address research on RDs.

3 May 2017 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
PDF file
JBJeffrey M. Beekman
Jeffrey M. Beekman
CWChiuhui Mary Wang
Chiuhui Mary Wang
SCSara Casati
Sara Casati
KTKatherine L. Tuggle
Katherine L. Tuggle
VGVincent A.M. Gulmans
Vincent A.M. Gulmans
KBKris De Boeck
Kris De Boeck